Restoration of miR-143 expression could inhibit migration and growth of MDA-MB-468 cells through down-regulating the expression of invasion-related factors

Tavanafar, Fatemeh; Safaralizadeh, Reza; Feizi, Mohammad Ali Hosseinpour; Mansoori, Behzad; Shanehbandi, Dariush; Mohammadi, Ali; Baradaran, Behzad

doi:10.1016/j.biopha.2017.04.119

Cited by 36 publications

(29 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, a decrease in cell proliferation and K‐RAS mRNA expression was observed. Moreover, metastasis‐related genes including MMP‐9 , CXCR‐4 , and Vimentin had declined expressions in this study (Tavanafar et al, ). Both DNA vectors and oligonucleotide mimics have advantages and limitations when compared.…”

Section: Discussionsupporting

confidence: 49%

miRNA‐143 replacement therapy harnesses the proliferation and migration of colorectal cancer cells in vitro

Karimi

Zeinali

Hosseinahli

et al. 2019

Journal Cellular Physiology

Self Cite

View full text Add to dashboard Cite

miR-143 is a tumor suppressor miRNA which its downregulation is frequently reported in colorectal cancer (CRC). This miRNA is a negative regulator of K-RAS, c-MYC, BCL-2, and MMP-9 genes which are engaged in tumor growth and metastasis.In the present study, miR-143 restoration was performed by transfection of the pCMV-miR-143 vector into the SW-480 CRC cells. Subsequently, alterations in proliferative and migratory potential of the cells were investigated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and wound-healing assays, respectively. Moreover, to detect apoptosis incidence in the transfected cells, 4',6-diamidino-2-phenylindole (DAPI) staining was used. Furthermore, mRNA levels of c-MYC, K-RAS, MMP-9, and BCL-2, as potential targets of miR-143, were assessed by quantitative Real-Time PCR (qRT-PCR). Also the expression levels of c-MYC, K-RAS, and MMP-9 proteins were investigated by the western blot analysis. Finally, the ratio of BAX to BCL-2 expression, as a potential marker of the response to apoptosis stimuli, was compared between the control and test groups. Furthermore, the trypan blue test was performed to determine the cell viability in cell suspension. According to the results, a decreased viability and migratory potential was observed for the miR-143 receiving cells.The DAPI staining also confirmed the occurrence of apoptosis. Moreover, BCL-2, K-RAS, MMP-9, and c-MYC mRNAs were significantly downregulated in the miR-143 grafted cells.The BAX/BCL-2 ratio also indicated a notable increase in the cells with miR-143 overexpression. In brief, miR-143 replacement could be considered as an effective strategy for the management of CRC and attenuating its invasive features.

show abstract

Section: Discussionsupporting

confidence: 49%

miRNA‐143 replacement therapy harnesses the proliferation and migration of colorectal cancer cells in vitro

Karimi

Zeinali

Hosseinahli

et al. 2019

Journal Cellular Physiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Even though KRAS mutations are detected in <5% of breast cancer patients, the mutation rate is reported to be 10%‐12% in the case of metastatic breast cancer 60 . The ectopic expression of MIR143 inhibits cell growth and cell invasion by silencing KRAS and the epithelial–mesenchymal transition, which is one of the key processes involved in metastasis 61 . The MAPK/ERK signaling pathway, which is the effector signaling pathway of RAS, plays a critical role in metastasis as well as cell proliferation.…”

Section: The Role Of Mir143‐3p On Rat Sarcoma Signaling Network In Vmentioning

confidence: 99%

Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview

et al. 2020

View full text Add to dashboard Cite

This is an open access article under the terms of the Creat ive Commo ns Attri bution-NonCo mmercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. AbstractRat sarcoma (RAS) is a well-known oncogene that plays important roles in cancer proliferation, cell survival and cell invasion. RAS exists as three major isoforms, Kirsten rat sarcoma (KRAS), Harvey rat sarcoma (HRAS) and neuroblastoma rat sarcoma (NRAS). Mutations of these genes account for approximately 30% of all cancers.Among them, KRAS mutations are the most common, responsible for 85%, followed by NRAS (12%) and HRAS (3%). Although the development of RAS inhibitors has been explored for over the past decade, so far, no effective inhibitor has been found.MicroRNA (miRNA) are a class of small non-coding RNA that control the gene expression of pleural target genes at the post-transcriptional level. MiRNA play critical roles in the physiological and pathological processes at work in cancers, such as cell proliferation, cell death, cell invasion and metastasis. MicroRNA-143 (MIR143) is known to function as a tumor suppressor in a variety of cancers. One of its known mechanisms is suppression of RAS expression and its effector signaling pathways, such as PI3K/AKT and MAPK/ERK. Within the last five years, we developed a potent chemically modified MIR143-3p that enabled us to elucidate the details of the KRAS signaling networks at play in colon and other cancer cells. In this review, we will discuss the role of MIR143-3p in those RAS signaling networks that are related to various biological processes of cancer cells. In addition, we will discuss the possibility of the use of MIR143 as a therapeutic drug for targeting RAS signaling networks. K E Y W O R D S AKT, ERK, KRAS positive circuit, MAPK, MIR143, PI3K, RAS | 1077 TOKUMARU eT Al.

show abstract

“…38,39 In addition, the biological function of tumor cells in distant metastasis from the primary lesion to the peripheral circulatory system has changed significantly. This method as a screening method is difficult for patients to accept.…”

Section: Discussionmentioning

confidence: 99%

Peripheral blood circulating microRNA‐4636/−143 for the prognosis of cervical cancer

Yin

Yang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Cervical cancer is the third leading cause of female death in the world. Serum microRNAs (miRNAs) are currently considered to be valuable as noninvasive cancer biomarkers, but their role in the prognosis of cervical cancer has not been elucidated. We aimed to find serum miRNAs that can be used as prognostic factors for cervical cancer. A traumatic pathological biopsy is the only reliable method for determining the severity of cervical cancer currently. Thus, noninvasive diagnostic markers are needed. The serological expression of candidate miRNAs were measured in 90 participants, including 60 patients with cervical cancer and 50 patients with cervical intraepithelial neoplasia. Two patients with cervical cancer were excluded from the study because of lack of data. miRNAs were evaluated by quantitative reverse transcription polymerase chain reaction. miR‐143/−4636 appeared specific for cervical cancer compared with cervical intraepithelial neoplasia (P < .001). The classification performance of validated miRNAs for cervical cancer [Area under the receiver operating characteristic curve (AUC) = 0.942] was better than that reached by squamous cell carcinoma antigen (SCC‐Ag; AUC = 0.727). Poor‐differentiation group has lower miR‐143/−4636 levels in serum (P < .05). miR‐4636 level was correlated gross tumor volume and the depth of invasion (P < .0001). In our study, we found a combination of miR‐143 and miR‐4636 that is independently and strongly associated with cervical cancer prognosis and can be used as a clinically prognostic factor.

show abstract

Restoration of miR-143 expression could inhibit migration and growth of MDA-MB-468 cells through down-regulating the expression of invasion-related factors

Cited by 36 publications

References 18 publications

miRNA‐143 replacement therapy harnesses the proliferation and migration of colorectal cancer cells in vitro

miRNA‐143 replacement therapy harnesses the proliferation and migration of colorectal cancer cells in vitro

Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview

Peripheral blood circulating microRNA‐4636/−143 for the prognosis of cervical cancer

Contact Info

Product

Resources

About